Estrogel gel for topical use, 0.6 mg/g, 80 g per bottle
Composition
Active ingredient: estradiol;
1 g of gel contains 0.6 mg of estradiol (as estradiol hemihydrate);
Excipients: carbomer 980, triethanolamine, 96% ethanol, purified water.
One squeeze of the bottle delivers 1.25 g of gel or 0.75 mg of estradiol.
Dosage Form
Gel for topical use.
Main physical and chemical properties: a colorless, transparent gel with an alcohol odor.
Pharmacotherapeutic group
Gonadal hormones and drugs used in disorders of the reproductive system. Estrogens. Simple preparations of natural and semisynthetic estrogens.
ATC code G03C A03.
Pharmacological Properties
Pharmacodynamics.
Estrogel belongs to the group of natural physiological estrogens. The active ingredient is chemically and biologically identical to endogenous human estradiol. Systemic administration of 17β-estradiol is possible through application to intact skin. Estrogel corrects estrogen deficiency in postmenopausal women or those who have undergone oophorectomy and alleviates menopausal symptoms. Estrogen prevents bone loss caused by menopause or oophorectomy.
When it binds to a specific receptor, estrogen forms a complex that primarily stimulates DNA and protein synthesis at the intracellular level and exerts metabolic effects at the level of “target” organs. The most active estrogen at the receptor level is estradiol, which is primarily synthesized in the ovarian follicles during the period from menarche to menopause. Estrogel also exerts an estrogenic effect on major “target” organs, acting not only on the ovaries, endometrium, and mammary glands, but also on the hypothalamus, pituitary gland, vagina, uterus, and liver. This produces an effect similar to that which normally occurs during the follicular phase of the menstrual cycle.
Transdermal administration of Estrogel avoids the so-called first-pass effect through the liver, which causes increased synthesis of angiotensinogen, LDL lipoproteins (triglycerides), and certain blood clotting factors.
Information derived from clinical studies
Relief of menopausal symptoms:
- relief of menopausal symptoms is observed from the first weeks of treatment;
- the nature of withdrawal bleeding or amenorrhea depends on the individually tailored dosing regimen of estrogen and progestogens.
Prevention of osteoporosis:
- Estrogen deficiency during menopause is associated with increased bone metabolism and a decrease in bone mass. The effect of estrogen on bone mineral density is dose-dependent. The protective effect lasts until the end of treatment. Upon discontinuation of hormone replacement therapy (HRT), bone mass decreases at the same rate as in women who are not receiving treatment.
- Data from the Women’s Health Initiative (WHI) and a meta-analysis indicate that the use of HRT in the form of estrogen monotherapy or in combination with progestins in otherwise healthy women reduces the risk of hip fractures, vertebral fractures, and other osteoporosis-related fractures. HRT may also reduce the risk of fractures in women with low bone mineral density and/or a diagnosed case of osteoporosis; however, data on this issue are limited.
Pharmacokinetics.
Within the first few hours after gel application (over 2–12 hours), estradiol levels reach values directly proportional to the dose and the area of skin to which the gel is applied.
Serum estradiol concentrations, as measured under experimental conditions 24 hours after daily application of 2.5 g and 5 g of gel to a 750 cm² skin surface area, averaged 75 pg/mL and 98 pg/mL, respectively (individual variations ranged from a minimum of 42 pg/mL to a maximum of 122 pg/mL when applying 2.5 g of gel, and from a minimum of 67 pg/ml to a maximum of 160 pg/ml when 5 g of gel was applied). On average, these levels remained stable and comparable for 72 hours after daily application of the gel, even over six consecutive treatment cycles, according to other experimental studies.
Blood estradiol levels remain constant in the same patient, even after an interval of several months (individual variations account for approximately 11%). Transdermal administration of estradiol avoids the first-pass effect in the liver: compared to physiological levels, circulating E2 and E1 levels range from 0.78 to 0.97; thus, these values are similar to maintained levels and comparable to those observed before menopause. After discontinuation of therapy, serum hormone levels return to baseline levels in approximately 76 hours; this also applies to the concentration of conjugated estradiol, which is excreted in the urine.
Estradiol
With transdermal application, approximately 10% of the applied estradiol dose is absorbed through the skin.
The half-life of estradiol in blood plasma is approximately 1 hour. The plasma clearance of these metabolites ranges from 650 to 900 liters/day/m².
The amounts of estradiol entering the bloodstream within 24 hours after applying the gel to the skin, with daily application at doses of 2.5 g and 5 g, are approximately 75 μg/day and 100 μg/day, respectively.
Estradiol is primarily metabolized in the liver to form estrone and conjugates (glucuronides, sulfates); these are significantly less active and are mainly excreted from the body in the form of glucuronides and sulfates. The metabolites also participate in enterohepatic circulation.
Indications
- Hormone replacement therapy (HRT) for the treatment of estrogen deficiency and symptoms of estrogen deficiency, particularly in cases of age-related or induced menopause: vasomotor symptoms (hot flashes, night sweats), trophic disorders of the genitourinary tract (atrophic vulvovaginitis, dyspareunia, urinary incontinence), and psychological disorders (sleep disturbances, asthenia).
- Prevention of postmenopausal osteoporosis in women at high risk for fractures, women who cannot tolerate other medications approved for the prevention of osteoporosis, or for whom these medications are contraindicated.
Experience with this therapy in women aged 65 years and older is limited.
Contraindications
- Hypersensitivity to the active ingredient or to any of the excipients.
- Breast cancer (diagnosed, suspected, or in the medical history).
- Diagnosed or suspected estrogen-dependent malignant tumors (e.g., endometrial cancer).
- Vaginal bleeding of unknown cause.
- Untreated endometrial hyperplasia.
- Idiopathic venous thromboembolic disorders, either current or in the medical history (e.g., deep vein thrombosis (DVT), pulmonary embolism).
- Known hypercoagulability (e.g., protein C, protein S, or antithrombin deficiency).
- Acute arterial thromboembolism, current or recent (e.g., angina pectoris, myocardial infarction).
- Acute liver disease, either current or in the medical history (until liver function test results return to normal).
- Current severe liver damage or impaired liver function with a history of persistently elevated liver function test levels.
- Porphyria.
Drug Interactions and Other Interactions
Estrogel does not stimulate excessive synthesis of liver proteins when used at usual doses: it has no adverse effect on lipid metabolism, blood clotting factors (fibrinogen, antithrombin II activity), circulating renin substrate levels, or sex hormone-binding proteins; thus, it does not contribute to the development of hypertriglyceridemia, diabetes mellitus, or hypertension.
At the same time, estrogen metabolism may be enhanced with concomitant use of enzyme inducers, particularly cytochrome P450 enzymes, such as anticonvulsants (e.g., phenobarbital, phenytoin, carbamazepine, meprobamate, and phenylbutazone), or antimicrobial agents (such as rifampin, rifabutin, nevirapine, and efavirenz).
CYP3A4 inhibitors, such as erythromycin, clarithromycin, ketoconazole, itraconazole, and grapefruit juice, may increase plasma estrogen concentrations and lead to the development of adverse reactions.
When used concomitantly with cyclosporine, reduced hepatic clearance of cyclosporine and increased plasma levels of cyclosporine, creatinine, and transaminases may occur.
Ritonavir and nelfinavir, although known as potent enzyme inhibitors, act as inducers when used concomitantly with steroid hormones.
Herbal preparations containing St. John’s wort (Hypericum perforatum) may enhance the metabolism of estrogens and progestins.
When administered transdermally, the drug bypasses the “first-pass” effect in the liver; therefore, transdermally applied estrogens and progestins are less affected by enzyme inducers than hormones administered orally.
Clinically, increased metabolism of estrogens and progestins may lead to a reduction in efficacy and changes in the nature of vaginal bleeding.
Special Considerations for Use
When treating postmenopausal symptoms, HRT should be used only if these symptoms affect quality of life. In any case, a thorough risk-benefit analysis must be conducted at least once a year. HRT should be continued only if the benefits outweigh the potential risks.
Data on the risks associated with HRT in the treatment of premature menopause are limited. However, due to the low absolute risk in younger women, the benefit-risk ratio in these women may be more favorable than in older women.
Clinical Evaluation and Monitoring
Before initiating or resuming HRT, the physician must obtain a complete personal and family medical history from the patient, and a medical examination (including the pelvic organs and breasts) should be performed to identify possible contraindications and ensure that appropriate precautions are taken when prescribing the medication. During treatment, regular medical examinations are also recommended; the frequency and type of these examinations should be tailored individually for each patient.
Women must be informed about changes in the condition of their breasts, which they should report to their doctor or nurse (see the “Breast Cancer” section below). Regular examinations, including mammography, should be performed during treatment. The frequency and type of screening methods are determined individually for each patient, in accordance with current clinical guidelines.
Conditions Requiring Monitoring
Examinations, including mammography, must be performed in accordance with established guidelines and tailored to the individual clinical needs of each patient.
If any of the conditions listed below are present, have occurred previously, and/or have worsened during pregnancy or prior hormone therapy, the patient should be under constant medical supervision. These conditions may, in some cases, recur or worsen during treatment with Estrogel, particularly uterine leiomyoma (fibroids) or endometriosis, as well as previous or current risk factors for thromboembolic complications (see above), risk factors for estrogen-dependent tumors (e.g., first-degree family history of breast cancer), hypertension, liver dysfunction (e.g., liver adenoma), diabetes mellitus with or without vascular complications, cholelithiasis, migraine or severe headaches, systemic lupus erythematosus, a history of endometrial hyperplasia, epilepsy, bronchial asthma, otosclerosis, and hereditary angioedema.
When prescribing progestins concomitantly, contraindications to their use should be taken into account: pregnancy—for progestins with androgenic activity; breast, ovarian, or endometrial cancer—for progestins with estrogenic activity.
Caution should be exercised in the presence of risk factors for cardiovascular complications, coronary and/or cerebrovascular complications, the likelihood of which increases in the presence of hypertension and/or in patients who smoke.
If changes are detected during breast examination, an additional gynecological examination of appropriate scope is required at any stage of treatment. It is also necessary to consult a doctor if irregular vaginal bleeding occurs (except for menstrual-like bleeding that occurs during a treatment break), headaches or vision problems, painful swelling of the lower extremities, or abdominal pain.
Reasons Requiring Immediate Discontinuation of Treatment
Treatment must be discontinued immediately if contraindications are identified or if any of the following conditions are present: jaundice or severe liver dysfunction, a significant increase in blood pressure, the onset of new episodes of migraine-like headaches, pregnancy, or suspected pregnancy.
Endometrial hyperplasia and carcinoma
In women with an intact uterus, the risk of developing endometrial hyperplasia and carcinoma increases with long-term use of estrogen alone. In patients taking estrogen alone, the risk of endometrial cancer has been observed to be 2–12 times higher than in women who do not take this medication, depending on the duration of treatment and the dose of estrogen (see the “Adverse Reactions” section). After discontinuation of treatment, the risk may remain elevated for at least 10 years.
Therefore, in patients with an intact uterus, the use of Estrogel must be accompanied by cyclic administration of progestogens. Concurrent administration of progestogens for at least 12 days per month/ 28-day cycle, or continuous treatment with a combination of estrogen and progestin in women who have not undergone a prior hysterectomy, prevents the increased risk associated with estrogen-only HRT.
Breakthrough bleeding or spotting may occur during the first few months of treatment. If these occur after some time during treatment and persist after discontinuation of therapy, the cause must be investigated, which may require an endometrial biopsy to rule out a malignant cause of these symptoms.
Estrogen monotherapy may lead to the development of precancerous changes and to the malignant transformation of residual endometriosis lesions. Currently, in women who have undergone hysterectomy for endometriosis, the addition of progestin to estrogen replacement therapy should be considered, as it is known that endometriotic lesions may persist in such cases.
Breast Cancer
General data indicate an increased risk of breast cancer in women taking a combination of estrogen and progestin, and possibly also in women receiving estrogen-only HRT, depending on the duration of HRT use.
Treatment with a combination of estrogen and progestin
In the randomized, placebo-controlled Women’s Health Initiative study, as well as in epidemiological studies, including the Million Women Study, an increased risk of breast cancer was demonstrated in women receiving combined estrogen and progestin therapy after approximately 3 years (see the “Adverse Reactions” section).
Estrogen-only therapy
At the same time, the WHI study did not observe an increased risk of breast cancer in women who had undergone a hysterectomy and were treated with estrogen-only HRT. Observational studies have generally shown a slight increase in the risk of breast cancer, which was significantly lower than in women receiving estrogen-progestin combinations (see the “Adverse Reactions” section).
The increased risk becomes significant after several years of use and returns to baseline within a few years (up to 5 years) after discontinuation of therapy.
With HRT, particularly with the combined use of estrogen and progestin, an increase in breast density is observed on mammograms, which may negatively affect the accuracy of breast cancer diagnosis using radiological methods.
Venous Thromboembolic Complications
The use of HRT is associated with a 1.3- to 3-fold increase in the relative risk of venous thromboembolism (VTE), i.e., deep vein thrombosis or pulmonary embolism. This complication is more likely to occur during the first year of HRT than later (see the “Adverse Reactions” section).
Patients diagnosed with thrombophilia are at increased risk of VTE, and HRT may further increase this risk. Therefore, HRT is contraindicated in these patients (see the “Contraindications” section).
Generally recognized risk factors for VTE include a personal or family history of VTE, severe obesity (BMI [body mass index] > 30 kg/m²), systemic lupus erythematosus (SLE), estrogen therapy, advanced age, major surgery, prolonged immobilization, pregnancy/postpartum period, and cancer. There is no consensus regarding the role of varicose veins in the development of venous thrombosis.
Patients with a history of VTE and patients with thrombophilia are at high risk for developing VTE. The use of HRT may increase this risk. In patients with a personal or family history of severe VTE or a history of recurrent spontaneous miscarriages, testing should be performed to rule out a predisposition to thrombophilia. If a patient has no history of venous thromboembolism, but she has close relatives who have experienced thromboembolism at a young age, screening may be offered, provided that the contraindications are carefully reviewed (screening identifies only a subset of thrombophilic disorders). If a thrombophilic disorder has been identified that manifests as thrombosis in relatives, or if the disorder is severe (e.g., antithrombin, protein S, or protein C deficiency, or a combination of disorders), OCT is contraindicated.
Until a thorough assessment of thrombophilic factors has been conducted and anticoagulant therapy has been initiated, ZGT is considered contraindicated for this group of patients. Women already receiving anticoagulants require special attention and an assessment of the risk-benefit ratio of ZGT.
The risk of VTE may be temporarily increased during prolonged immobilization, severe trauma, or major surgical procedures. As with all patients, special attention should be paid to VTE prevention during the postoperative period. Since prolonged immobilization is a consequence of elective surgical procedures, especially abdominal surgery or orthopedic surgery on the lower extremities, one preventive measure to consider is temporarily discontinuing HRT for 4–6 weeks prior to surgery. HRT may be resumed only after the patient has fully regained mobility.
If VTE develops after treatment has begun, treatment should be discontinued. Patients should be informed of the need to seek immediate medical attention if they experience any symptoms suggestive of thromboembolism (e.g., painful swelling of the legs, sudden chest pain, or shortness of breath).
Coronary Artery Disease
Controlled randomized trials have not demonstrated any preventive effects against myocardial infarction in women with or without ischemic heart disease who received HRT with a combination of estrogen and progestin or estrogen alone.
Treatment with a combination of estrogen and progestin
The relative risk of developing ischemic heart disease is slightly increased with HRT using a combination of estrogen and progestin. Since the baseline absolute risk of developing ischemic heart disease depends significantly on age, the number of additional cases of ischemic heart disease resulting from the use of estrogen and progestin is very small in healthy women approaching menopause, but it increases in older women.
Estrogen-only therapy
In randomized controlled trials, no increased risk of ischemic heart disease was observed in women who had undergone hysterectomy and were receiving estrogen-only therapy.
Cerebrovascular complications (ischemic stroke)
Treatment with a combination of estrogen and progestin and estrogen-only therapy increases the risk of ischemic stroke by a factor of 1.5 or less. The relative risk does not depend on age or the time elapsed since the onset of menopause. However, since the baseline risk of stroke depends significantly on age, the overall risk of stroke in women receiving HRT will increase with age (see the “Adverse Reactions” section).
Ovarian Cancer
Ovarian cancer is much less common than breast cancer. Data from epidemiological studies, as analyzed in a large meta-analysis, indicate a slight increase in risk among women who received HRT with estrogen alone or a combination of estrogen and progestin, which becomes apparent within 5 years of treatment and gradually decreases after treatment is discontinued.
Based on the results of other studies, including the WHI study, a similar or slightly lower risk is suggested with the use of combined HRT (see the “Adverse Reactions” section).
Other Conditions
Estrogens may cause fluid retention; therefore, patients with impaired cardiac or renal function should be monitored closely. Patients with end-stage renal failure require particularly close monitoring, as elevated blood levels of Estrogel’s active ingredients are to be expected.
Changes in glucose tolerance have been observed in some patients taking estrogen/progestin preparations. Estrogel may increase insulin sensitivity and accelerate its elimination. In patients with diabetes mellitus, blood glucose levels should be closely monitored during the first few months of hormone replacement therapy.
There is evidence of an increased risk of surgically confirmed gallstone disease in postmenopausal women who have taken estrogens.
The use of estrogens may alter the results of certain endocrinological tests and liver function tests.
Patients with hypertriglyceridemia who are receiving estrogen monotherapy or hormone replacement therapy should be closely monitored, given the reported isolated cases of marked increases in plasma triglyceride levels, which may lead to the development of pancreatitis.
Estrogens increase thyroid-binding globulin (TBG) levels, leading to an increase in circulating thyroid hormone levels, as measured by protein-bound iodine, T4 concentrations (column or radioimmunoassay), or T3 concentrations (radioimmunoassay). The increase in T3 levels is reduced, reflecting elevated TBG, while free T4 and T3 concentrations remain unchanged. Serum concentrations of other binding proteins may increase, such as corticosteroid-binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased concentrations of circulating corticosteroids and sex steroid hormones, respectively. Concentrations of free or biologically active hormones remain unchanged. Concentrations of other plasma proteins may increase (angiotensin/renin substrate, alpha-1-antitrypsin, ceruloplasmin).
Chloasma may rarely occur, especially in women with a history of chloasma during pregnancy. Women prone to chloasma should minimize exposure to sunlight or ultraviolet radiation while on HRT.
There is no convincing evidence of improved cognitive function with HRT use. The WHI study showed a trend toward a possible increased risk of dementia in women with long-term HRT use who begin combination therapy withestrogen and medroxyprogesterone acetate at age 65 or older. It remains unknown whether these findings apply to younger postmenopausal women or to the use of other types of HRT.
Close monitoring of patients is necessary in the following cases:
ischemic stroke associated with atherosclerosis, intracerebral hemorrhage, retinal vein occlusion, obesity due to the risk of venous thrombosis, bed rest, and preparation for elective surgery (it is advisable to discontinue treatment 1 month before surgery). Patients with a history of benign skin tumors, prolactin-secreting pituitary tumors, osteospongiosis, or pruritus require close monitoring.
Use during pregnancy or breastfeeding.
Do not use during pregnancy or breastfeeding. Treatment with Estrogel should be discontinued immediately if pregnancy is confirmed or suspected. The risk of pregnancy termination and suppression of lactation are not indications for estrogen therapy. According to epidemiological studies, there is no evidence of an increased risk of congenital fetal malformations resulting from the use of estrogen in early pregnancy when pregnancy is diagnosed late. However, it should be noted that there is no need to artificially terminate the pregnancy in women who took estrogens or estrogen-progestin combinations in the early stages of pregnancy if the pregnancy is diagnosed late. To date, epidemiological studies in pregnant women have not revealed any evidence of teratogenic or fetotoxic effects following accidental exposure to therapeutic doses of estrogen.
Effect on reaction time when driving or operating machinery.
No data are available, but the possibility of nervous system reactions—such as dizziness and drowsiness—should be considered.
Dosage and Administration
The drug is administered transdermally.
The dosage should be adjusted according to individual needs.
For the treatment of postmenopausal symptoms, the minimum effective dose is 1.25 g of gel per day (= 0.75 mg of estradiol); use is recommended for 21–28 days per month. The dose varies depending on the patient’s needs, with an average dose of 2.5 g of gel per day. When starting or continuing treatment for menopause-related symptoms, the minimum effective dose should be used for the shortest possible period (see also the “Special Considerations for Use” section).
For women with an intact uterus, long-term treatment with estrogen without progestin is not recommended due to the potential risk of adverse endometrial events (glandular-cystic hyperplasia, dysplasia, which increases the risk of endometrial cancer); treatment should be administered for at least 3 consecutive weeks, followed by a 1-week break, while progestins are administered orally for 12–14 days per month/28-day cycle. Treatment may be administered from day 1 to day 25 of the month concurrently with oral progestin, if necessary. Bleeding may occur during the one-week break due to a decrease in hormone levels. It is recommended to use only those progestogens that are approved for use in combination with estrogen.
At the same time, long-term estrogen therapy may be indicated for women who have undergone a hysterectomy or who experience pronounced symptoms of estrogen deficiency after discontinuing treatment. In the latter case, progesterone may be prescribed for the first 12–14 days of each month. Only in cases of a confirmed diagnosis of endometriosis is the concurrent use of progestins not recommended for women who have undergone a hysterectomy.
The dosage may be adjusted as needed after 2–3 treatment cycles depending on clinical symptoms, specifically:
- if symptoms of hyperestrogenism appear, such as breast tenderness, a feeling of fullness in the abdomen and pelvis, anxiety, nervousness, or aggression, the dose should be reduced;
- if symptoms of hypoestrogenism occur, such as persistent hot flashes, vaginal dryness, headaches, sleep disturbances, asthenia, or a tendency toward depression, the dose should be increased.
If a single dose is missed, do not take a double dose the next day. If the next dose is due in less than 12 hours, wait until the next scheduled time to apply the dose. If the next dose is due in more than 12 hours, apply the missed dose immediately and take the next dose at the usual time. Missing doses increases the risk of spotting and bleeding.
Directions for Use
It is recommended to apply the dose to the largest areas of skin, preferably the forearm, shoulder, and/or upper arm, or to a large area of intact skin. Avoid applying the gel to the skin of the breast or the mucous membranes of the vulvovaginal area.
Patients should apply the gel themselves, in the evening or in the morning, preferably after their evening or morning hygiene routine, at the same time each day. To do this, remove the cap from the bottle and press firmly on the pump dispenser, holding out the other hand to catch the gel. One press of the pump dispenses 1.25 g of gel, which is equal to half the daily dose. The amount dispensed on the first press may be inaccurate. It is recommended to discard it. The bottle is designed for 64 pumps. After 64 pumps, the amount of gel dispensed per pump may be less than required. Therefore, it is not recommended to use the bottle after 64 pumps of the dispenser.
Apply the gel in a thin layer to the skin in the areas mentioned above. If the skin remains greasy for more than 3 minutes after application, this means that the area of skin covered with gel was too small. Try to apply the gel to a larger area of the body the next time you use it.
Wash your hands thoroughly after applying the gel.
Children.
This medication should not be used in pediatric practice.
Overdose
In case of overdose, headaches, nervousness, breast tenderness, vaginal bleeding, and the symptoms listed in the “Adverse Reactions” section (signs of excessive estrogen) may occur. These symptoms usually resolve upon discontinuation of treatment or reduction of the dose.
Side Effects
Listed below are all possible side effects, particularly those observed in up to 10% of patients.
The frequency of adverse reactions was assessed according to the following criteria: > 1/100, < 1/10 – common; > 1/1,000, < 1/100 – uncommon.
Psychiatric disorders: common—nervousness, depressive disorders.
Nervous system: common—headache; uncommon—migraine, dizziness, drowsiness.
Cardiovascular system: uncommon—deep or superficial vein thrombosis, thrombophlebitis.
Gastrointestinal system: common—abdominal pain, stomach cramps, bloating, nausea, vomiting.
Hepatobiliary system: uncommon—abnormal liver function tests, liver adenoma, cholelithiasis.
Skin and subcutaneous tissue disorders: uncommon—skin rash, itching, chloasma.
Reproductive system and mammary glands: common—dysmenorrhea, menorrhagia, bleeding (spotting), menstrual irregularities, leukorrhea; uncommon – benign breast tumors, endometrial polyps, enlargement of uterine leiomyomas, endometriosis, mastodynia, progression of estrogen-dependent tumors.
Musculoskeletal and connective tissue disorders: common—muscle cramps, pain in the extremities; uncommon—arthralgia.
General disorders and administration site conditions: infrequently—peripheral edema, sodium retention, sensation of swelling, changes in body weight.
Adverse reactions observed in clinical trials.
Nervous system: restlessness.
Respiratory, thoracic, and mediastinal disorders: sinusitis, rhinitis.
Cardiovascular system: palpitations.
Hepatobiliary system: diarrhea.
Reproductive system: breast pain, metrorrhagia, vaginitis, vaginal bleeding, endometrial disorders, changes in Pap smear results.
General disorders: infections, back pain, pain, flu-like syndrome, asthenia.
Adverse reactions reported during clinical trials and in the postmarketing period.
Benign, malignant, and unspecified neoplasms (including cysts and polyps): uterine fibroids.
Immune system disorders: exacerbation of hereditary angioedema.
Metabolic and nutritional disorders: increased appetite, hypercholesterolemia.
Psychiatric disorders: changes in libido and mood, anxiety, insomnia, apathy, emotional lability, impaired concentration, euphoria, agitation.
Nervous system disorders: paresthesia, tremor.
Ocular disorders: visual disturbances, dry eyes.
Cardiovascular system: palpitations, increased blood pressure, cerebral circulation disorders, superficial phlebitis, purpura.
Respiratory system, thoracic, and mediastinal disorders: shortness of breath, runny nose.
Gastrointestinal system: constipation, dyspepsia, diarrhea, rectal symptoms.
Hepatobiliary system: impaired liver function and bile flow, cholestatic jaundice.
Skin and subcutaneous tissue disorders: acne, hair loss, dry skin, contact dermatitis, eczema, nail plate changes, nodular skin lesions, hirsutism.
Musculoskeletal and connective tissue disorders: joint symptoms.
Renal and urinary system: increased urinary frequency and urgency, urinary incontinence, cystitis, discolored urine, hematuria.
Reproductive system: breast tenderness/pain/tension, vaginal discharge, vulvar/vaginal symptoms, breast enlargement, endometrial hyperplasia, uterine symptoms.
General disorders and administration site conditions: irritation, pain, hyperhidrosis, increased fatigue, abnormal laboratory test results, asthenia, hyperthermia, flu-like symptoms, malaise.
Other adverse reactions that have occurred with combined estrogen-progestin therapy.
Gallbladder dysfunction, hemorrhagic rash.
Risk of ovarian cancer.
Long-term use of HRT with estrogen alone or a combination of estrogen and progestin is associated with a slight increase in the risk of ovarian cancer (see the “Special Considerations for Use” section). A meta-analysis of 52 epidemiological studies demonstrated an increased risk of ovarian cancer in women currently using HRT, compared with women who have never used HRT (relative risk (RR) 1.43, 95% confidence interval (CI): 1.31–1.56). Among women aged 50 to 54, 5 years of HRT use results in one additional case per 2,000 women. Among women aged 50 to 54 who do not use HRT, 2 out of every 2,000 women develop ovarian cancer over a 5-year period.
Risk of venous thromboembolism.
HRT is associated with a 1.3- to 3-fold increased risk of venous thromboembolism, such as deep vein thrombosis or pulmonary embolism. The disease is most likely to develop during the first year of HRT use (see the “Special Considerations for Use” section). The results of the WHI studies are presented in Table 1.
Table 1
WHI Study: Additional Risk of Venous Thromboembolism Over 5 Years of Use
| Age range
(years) |
Incidence rate per 1,000 women in the placebo group over 5 years | Relative risk with 95% CI | Additional cases per 1,000 women using HRT |
| Oral estrogen only* | |||
| 50–59 | 7 | 1.2 (0.6–2.4) | 1 (-3 – 10) |
| Combination of oral estrogen and progestin | |||
| 50–59 | 4 | 2.3 (1.2–4.3) | 5 (1–13) |
| *Study involving women who have undergone hysterectomy. | |||
Risk of developing coronary heart disease.
The risk of developing ischemic heart disease is slightly increased in patients aged 60 years and older who use HRT with a combination of estrogen and progestin (see the “Special Considerations for Use” section).
Risk of ischemic stroke.
The relative risk of ischemic stroke increases 1.5-fold in patients receiving either estrogen monotherapy or combined estrogen-progestin therapy. The risk of hemorrhagic stroke does not increase during HRT.
The relative risk does not depend on age or duration of treatment; however, the risk itself is clearly age-dependent, so the overall risk of stroke increases with age in patients using HRT (see the “Special Considerations” section).
Table 2
Pooled data from all WHI studies: additional risk of ischemic stroke* over 5 years of use
| Age (years) | Incidence rate per 1,000 women in the placebo group over 5 years | Relative risk with 95% CI | Additional cases per 1,000 women using HRT over 5 years |
| 50–59 | 8 | 1.3 (1.1–1.6) | 3 (1–5) |
| *No distinction was made between ischemic and hemorrhagic stroke. | |||
Risk of breast cancer.
An increased risk of breast cancer of up to 2 times has been reported in women who received treatment with a combination of estrogen and progestin for more than 5 years.
The risk associated with estrogen-only therapy is significantly lower than that associated with estrogen-progestin combination therapy.
The level of risk depends on the duration of treatment (see the “Special Considerations” section).
The results of the largest randomized, placebo-controlled study (WHI) and the largest epidemiological study (MWS) are presented below.
Table 3
MWS (Million Women Study): Estimation of the Additional Risk of Breast Cancer After 5 Years of Treatment
| Age range (years) | Additional cases per 1,000 women who have never used HRT over 5 years* | Relative risk# with 95% CI | Additional cases per 1,000 women who used HRT over 5 years (95% CI) | |||
| Estrogen-only HRT | ||||||
| 50–65 | 9–12 | 1.2 | 1–2 (0–3) | |||
| HRT with a combination of estrogen and progestin | ||||||
| 50–65 | 9–12 | 1.7 | 6 (5–7) | |||
| * Based on baseline incidence rates in developed countries.
# Overall risk ratio. The relative risk is not constant; it increases with longer duration of treatment. Note: Since baseline breast cancer incidence rates vary across EU countries, the number of additional breast cancer cases also varies proportionally.
Table 4 The WHI Study in the U.S.: Additional Risk of Breast Cancer After 5 Years of Treatment |
||||||
| Age range (years) | Incidence rate per 1,000 women in the placebo group over 5 years | Relative risk with 95% CI | Additional cases per 1,000 women using HRT over 5 years (95% CI) | |||
| HR#, estrogen-only | ||||||
| 50–79 | 21 | 0.8 (0.7–1.0) |
|
|||
| COC + MPA##, estrogen-progestin‡ | ||||||
| 50–79 | 17 | 1.2 (1.0–1.5) | +4 (0–9) | |||
| * In women without a uterus, the WHI study did not show an increased risk of breast cancer.
‡ When the analysis was limited to women who had not used HRT prior to the start of the study, no increased risk was observed during the first 5 years of treatment; after 5 years, the risk was higher compared to those not using HRT. #CEE – conjugated equine estrogen. ##MPA – medroxyprogesterone acetate. |
||||||
Risk of endometrial cancer.
The risk of developing endometrial cancer is approximately 5 per 1,000 women with a uterus who do not use HRT.
Hormone replacement therapy containing estrogen alone is not recommended for women with a uterus, as it increases the risk of endometrial cancer (see the “Special Considerations” section).
Depending on the duration of treatment and the dose of estrogen, the increased risk of endometrial cancer, according to epidemiological studies, ranged from 5 to 55 additional cases per 1,000 women aged 50 to 65 years.
Adding progestin to estrogen-only therapy for at least 12 days per cycle can prevent this increased risk. In the Million Women Study (MWS), the use of combined (sequential or continuous) HRT for five years did not increase the risk of endometrial cancer [OR 1.0 (0.8–1.2)].
The following side effects have been reported with combined estrogen and progestin therapy:
- benign and malignant estrogen-dependent tumors, such as endometrial cancer;
- venous thromboembolic complications (i.e., deep vein thrombosis of the pelvis and lower extremities or pulmonary embolism). These complications occur more frequently in women receiving HRT than in women who do not receive HRT. Additional information is provided in the “Contraindications” and “Special Precautions for Use” sections;
- myocardial infarction and stroke;
- gallbladder disease;
- biliary tract infections;
- skin and subcutaneous tissue disorders: chloasma, erythema multiforme, erythema nodosum, vasculitis;
- possible dementia in patients aged 65 years and older (see the “Special Considerations for Use” section).
The following adverse events require dose adjustment depending on signs of estrogen deficiency or excess:
Signs of estrogen deficiency: hot flashes, frequent headaches, migraines, vaginal dryness, eye irritation when wearing contact lenses;
signs of excessive estrogen levels: nausea, vomiting, abdominal cramps, bloating, breast tenderness, irritability, edema, heaviness in the legs, increased cervical mucus secretion;
other possible side effects: uterine bleeding (other causes, such as endometriosis, must be ruled out), galactorrhea (pituitary adenoma must be ruled out), exacerbation of epilepsy, chloasma, or melanosis.
Reporting Suspected Adverse Reactions
After a drug is approved, it is important to collect reports of suspected adverse reactions. This allows for monitoring the benefit-risk ratio of the drug’s use. Healthcare professionals should report suspected adverse reactions through the national pharmacovigilance system.
Shelf life
3 years.
Storage Conditions
Store at a temperature not exceeding 25 °C in places inaccessible to children.
Packaging
80 g per bottle with a dispenser; 1 bottle per cardboard box.
Dispensing Category
By prescription only.
Manufacturer
1) Bezen Manufacturing Belgium;
2) Bezhen International Laboratories.
Manufacturer’s location and address of its place of business.
1) Grot-Bigarenstraat 128, 1620 Drogenbos, Belgium;
2) 13 Rue Perrier, Montrouge, 92120, France.
Applicant
Bezen Healthcare SA.
Location of the applicant.
80 Rue Washington, 1050 Ixelles, Belgium.
Similar products
Products from the same category










